Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection

Participants needed: 84
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Sep 25, 2026Locations: 1
Eligibility criteria

Have given written informed consent to participate in this study in accordance w... [+2]

Have evidence of any clinically significant active or chronic disease. [+6]

Read more
Status: Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.

Participants needed: 1,560
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Sep 16, 2026Locations: 135
Eligibility criteria

Participant must be ≥18 years of age inclusive, or the legal age of consent in t... [+3]

Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar st... [+6]

Read more
Status: Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.

Participants needed: 3,003
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Ascletis Pharma (China) Co., LimitedUpdated: Sep 16, 2026Locations: 122
Eligibility criteria

Participant must be ≥18 years of age inclusive, or the legal age of consent in t... [+5]

Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types... [+6]

Read more